Clarke S E, Clarke D G, Prescod N
Department of Nuclear Medicine, Guy's and St. Thomas' Hospital, London, UK.
Nucl Med Commun. 1999 Aug;20(8):711-7. doi: 10.1097/00006231-199908000-00005.
A postal survey was conducted in the UK in 1996 to determine the facilities available and the level of activity at centres where radionuclide therapy was practised in 1995. A response rate of 79% indicated that 102 centres were providing radionuclide therapy, with 339 clinicians holding ARSAC certificates, 57% of whom were clinical oncologists. There were 84 beds available for therapy and the total number of patients treated was 11,435. Patient numbers treated by disease or procedure were: haematological, 569 (5%); benign thyroid disease, 9059 (79.2%); malignant thyroid disease, 911 (8%); bone pain palliation, 425 (3.5%); radiosynovectomy, 321 (2.8%); neuroendocrine tumour therapy, 76 (0.7%); and intra-cavitary, 56 (0.5%). The total amounts of activity of individual radiopharmaceuticals administered in GBq were: 131I, 16,695; 90Y-colloid, 88; 32P, 94.6; 131I-MIBG, 646; 89Sr, 57.6; and 186Rh-HEDP, 16. Average waiting times varied from 1 to 5 weeks, with a range of 0 to 52 weeks for some therapies. Most centres had the services of a physicist available. Compared with teaching hospitals, the 61 district hospitals had fewer allocated beds, but treated almost half of all patients. The numbers of therapies undertaken were increasing at many centres and this has implications for long-term planning.
1996年在英国进行了一项邮政调查，以确定1995年开展放射性核素治疗的中心所具备的设施及活动水平。79%的回复率表明有102个中心提供放射性核素治疗，339名临床医生持有ARSAC证书，其中57%为临床肿瘤学家。有84张治疗床位，接受治疗的患者总数为11435人。按疾病或治疗程序划分的治疗患者数量如下：血液系统疾病，569例（5%）；良性甲状腺疾病，9059例（79.2%）；恶性甲状腺疾病，911例（8%）；骨痛缓解治疗，425例（3.5%）；放射性滑膜切除术，321例（2.8%）；神经内分泌肿瘤治疗，76例（0.7%）；腔内治疗，56例（0.5%）。所施用的各放射性药物的活度总量（以GBq计）分别为：131I，16695；90Y胶体，88；32P，94.6；131I-MIBG，646；89Sr，57.6；186Rh-HEDP，16。平均等待时间从1至5周不等，某些治疗的等待时间范围为0至52周。大多数中心有物理学家提供服务。与教学医院相比，61家地区医院的分配床位较少，但治疗了几乎一半的患者。许多中心开展的治疗数量在增加，这对长期规划有影响。
